[16]
Nascimento IJDS, de Aquino TM, Silva-júnior EF. Drug repurposing : A strategy for discovering inhibitors against emerging viral infections. Curr Med Chem 2021; 28(15): 2887-942.
[18]
José dos Santos Nascimento I, Mendonça de Aquino T, Fernando da Silva Santos-Júnior P, Xavier de Araújo-Júnior J, Ferreira da Silva-Júnior E. Molecular modeling applied to design of cysteine protease inhibitors - a powerful tool for the identification of hit compounds against neglected tropical diseases. Front Comput Chem 2020; 5: 63-110.
[21]
Faheem; Kumar, B.K.; Sekhar, K.V.G.C.; Kunjiappan, S.; Jamalis, J.; Balaña-Fouce, R.; Tekwani, B.L.; Sankaranarayanan, M. Druggable targets of sars-cov-2 and treatment opportunities for covid-19. Bioorg Chem 2020; 104104269
[37]
Fraser B, Beldar S, Hutchinson A, et al. Crystal structure of human tmprss2 in complex with nafamostat. Protein Data Bank 2021.
[41]
Xiu S, Dick A, Ju H, et al. Inhibitors of sars-cov-2 entry: Current and future opportunities. J Med Chem 2020; 63(21): 12256-74.
[44]
Bittmann S. COVID 19: Camostat and the role of serine protease entry inhibitor tmprss2. J Regen Biol Med 2020; 2: 1-2.
[47]
Shrimp JH, Kales SC, Sanderson PE, Simeonov A, Shen M, Hall MD. An enzymatic tmprss2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of covid-19 ACS Pharmacol Transl Sci 2020.
[54]
Yu W, Jr ADM. Chapter 5 computer-aided drug design methodsAntibiot Methods Protoc. 2017; 1520: pp. 85-106.
[71]
Christoph G, Krishna P, Kendra E. L.; Marco, C.; Patrick D., F.; Zi-Fu, W.; Guilhem, T.; Shreya, P.; Alec, S.; Anthony, C.; Colin, H.; Minko, G.; Alexander, R.; Noam, L.; Erez, Y.; Roni, L.; Henry D., H.; Vedat, D.; Thanos D., H.; Konstantin, F.; Justin J., P.; Alexander, C.; Igor, D.; Alla, P.; Yurii, M.; Dmytro, R.; Olga, T.; Irina, Y.; Christian C., G.; Ryan, Y.; Dave, P.; Anders M., N.; Mark N., N.; Robert A., D.; Gerhard, W.; Jamie, K.; Haribabu, A. A multi-pronged approach targeting sars-cov-2 proteins using ultra-large virtual screening. ChemRxiv 2020; 2.
[72]
Qing X, Lee XY, De Raeymaeker J, et al. Pharmacophore modeling: Advances, limitations, and current utility in drug discovery. J Receptor Ligand Channel Res 2014; 7: 81-92.
[75]
Nguyen B. In silico pharmacophore study and structural optimization
of nafamostat yield potentially novel transmembrane protease
serine 2 (tmprss2) inhibitors which block the entry of sars-cov-2
virus into human cells 2020; 2
[76]
Choudhary S, Silakari O. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of sars-cov-2 with ace2 and other proteases involved in covid-19. Elsevier B.V. 2020; p. 289.
[84]
Gns HS, Gr S. An update on drug repurposing: Re-written saga ofthe drug’s fate 2019; 110: 700-16.
[86]
Sonawane K, Barale SS, Dhanavade MJ, et al. Homology modeling and docking studies of TMPRSS2 with experimentally known inhibitors camostat mesylate, nafamostat and bromhexine hydrochloride to control SARS-coronavirus-2. ChemRxiv 2020.
[88]
Napolitano F, Gambardella G, Carrella D, Gao X, di Bernardo D. Computational drug repositioning and elucidation of mechanism
of action of compounds against SARS-CoV-2 arXiv preprint
arXiv:200407697, 2020.
[91]
Jaimes JA, Millet JK, Whittaker GR. Proteolytic cleavage of the
sars-cov-2 spike protein and the role of the novel s1/s2 site iScience
2020; 23: 101212
[96]
Coban M, Morrison J, Freeman WS, Radisky E, Le Roch K, Caulfield T. Targeting Tmprss2, S-Protein:Ace2, and 3CLpro for synergetic inhibitory engagement. ChemRxiv 2020.
[97]
Rensi S, Keys A, Lo Y-C, et al. Homology modeling of tmprss2 yields candidate drugs that may inhibit entry of sars-cov-2 into human cells. ChemRxiv 2020.
[98]
Mulgaonkar NS, Wang H, Mallawarachchi S, Ruzek D, Martina B, Fernando S. Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for covid-19. bioRxiv 2020.
[104]
Yadav PK, Jaiswal A, Singh RK. In silico study on spice-derived antiviral phytochemicals against sars-cov-2 tmprss2 target 2020.
[106]
P., H.; A., F.. Exploring structurally diverse plant secondary metabolites
as a potential source of drug targeting different molecular
mechanisms of severe acute respiratory syndrome coronavirus-2
(sars-cov-2) pathogenesis. An in silico Approach 2020; 2: 1-38..
[112]
Dave GS, Rakholiya KD, Kaneria MJ, et al. High affinity interaction of solanum tuberosum and brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. Phytother Res 2020; 34(12): 3400-10.
[113]
Roomi M, Khan Y. Potential compounds for the inhibition of TMPRSS2. ChemRxiv 2020.
[116]
De Jesus M, Gaza J, Junio HA, Nellas R. Molecular docking of secondary metabolites from Psidium Guajava L. and Piper Nigrum L. to COVID-19 associated receptors ACE2, spike protein RBD, and TMPRSS2. ChemRxiv 2020.
[119]
Silva LR, da Silva Santos-Júnior PF, de Andrade Brandão J, et al. Druggable targets from coronaviruses for designing new antiviral drugs. Bioorg Med Chem 2020; 28(22)115745